RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $92,987 | -7.6% | 5,639 | 0.0% | 0.03% | -23.5% |
| Q1 2023 | $100,600 | -86.8% | 5,639 | -88.8% | 0.03% | -90.8% |
| Q1 2020 | $764,000 | -33.7% | 50,221 | 0.0% | 0.37% | -22.3% |
| Q4 2019 | $1,153,000 | +6.4% | 50,221 | 0.0% | 0.48% | +5.3% |
| Q3 2019 | $1,084,000 | -51.0% | 50,221 | -50.0% | 0.45% | +9.2% |
| Q2 2019 | $2,210,000 | +60.5% | 100,442 | +100.0% | 0.41% | -15.2% |
| Q1 2019 | $1,377,000 | – | 50,221 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |